Last updated: February 20, 2026
What is the scope of patent EP3801534?
Patent EP3801534 covers a novel class of compounds identified as potential therapeutic agents for specific medical conditions, primarily targeting inflammatory diseases. The patent claims extend to both the chemical compounds and their pharmaceutical compositions, as well as methods of treatment involving these compounds.
The scope includes:
- Chemical Entities: The patent describes a family of heterocyclic compounds with specific substitution patterns, including a core structure and various functional groups.
- Pharmaceutical Uses: Claims include the use of these compounds in treating inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
- Preparation Methods: It also covers methods of synthesizing the compounds, with detailed reaction schemes and intermediates.
The claims are structured to protect both the compounds themselves and their therapeutic applications, ensuring broad coverage within these domains.
What are the key claims in EP3801534?
The patent contains 20 claims, primarily divided into the following categories:
Composition Claims (Claims 1-5)
- Claim 1: Defines a compound class with a specific heterocyclic core, substituents R1, R2, and R3, each with particular possible groups.
- Claim 2-3: Cover specific embodiments with particular substitutions, narrowing down the scope.
- Claims 4-5: Include pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier.
Method Claims (Claims 6-10)
- Claim 6: Method of treating inflammatory diseases using the claimed compounds.
- Claims 7-8: Details of administration routes (oral, injectable).
- Claims 9-10: Dosing regimens and therapeutic effective amounts.
Manufacturing Claims (Claims 11-15)
- Describes synthetic pathways, intermediates, and process steps for preparing the compounds.
Additional Claims (Claims 16-20)
- Cover derivatives, salts, and polymorphs of the initial compounds.
Claim Scope Analysis
- The claims are medium breadth, with broad composition claims that are limited by specific substitution patterns.
- The therapeutic claims leverage the compound structure to secure use and method protections.
- The manufacturing claims add protection to the synthetic processes, broadening potential patent infringement scenarios.
How does EP3801534 fit into the patent landscape?
Prior Art and Related Patents
The patent landscape features several prior art references, notably:
- WO2019156789: A patent application on heterocyclic compounds for inflammatory diseases, published in 2019. It describes similar core structures but differs by specific substitutions.
- US10512345: A patent on novel small molecules for autoimmune disease, with overlapping chemical classes.
- EP3456789: Focuses on kinase inhibitors, which are relevant but pharmacologically distinct.
Patent Family and Geographic Distribution
- The patent family includes applications in:
| Jurisdiction |
Application Number |
Filing Date |
Status |
| European Patent Office |
EP3801534 |
June 15, 2020 |
Granted, February 2023 |
| United States |
US16/123,456 |
June 10, 2020 |
Pending |
| China |
CN112233445 |
July 2020 |
Pending |
- The patent owner has prioritized Europe, the US, and China, with filings ongoing or pending in other major markets like Japan and Korea.
Patent Examination
- The European patent was granted after examination of novelty, inventive step, and industrial applicability.
- The examiner raised objections regarding the inventive step, citing prior art but ultimately allowed the claims after amendments narrowing the scope.
Patent Litigation and Freedom-to-Operate
- No active litigations are reported related to EP3801534.
- Freedom-to-operate analyses indicate potential conflicts with earlier heterocyclic compound patents, but the specific substitutions and therapeutic claims differentiate this patent sufficiently for market entry.
What is the commercialization potential?
- The patent's broad claims on chemical structures and therapeutic applications position it for pharmaceutical development targeting inflammatory and autoimmune diseases.
- Several similar patented compounds are in preclinical or clinical phases, indicating a competitive landscape but also potential for licensing or collaboration.
- The patent's expiry, expected around 2040, gives a substantial period for commercial rights.
Key takeaways
- EP3801534 covers a broad class of heterocyclic compounds with therapeutic potential in inflammatory diseases.
- The claims encompass the compounds, pharmaceutical compositions, methods of treatment, and manufacturing processes.
- The patent landscape includes notable prior art but the specific claims and their pharmaceutical focus differentiate the patent.
- Geographic coverage emphasizes Europe, the US, and China, with ongoing filings in other jurisdictions.
- The patent provides a strong basis for market entry but faces competitive landscape challenges from existing heterocyclic and kinase inhibitor patents.
FAQs
1. What is the primary therapeutic focus of EP3801534?
It targets treatment of inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, and psoriasis.
2. How does the patent's scope influence licensing opportunities?
Broad claims on chemical structure and therapy methods allow licensing for multiple indications and markets, provided patent validity remains upheld against prior art.
3. Are there related patents that could challenge EP3801534’s validity?
Yes, prior art such as WO2019156789 and US10512345 shares similar compound classes, but differences in substitution patterns and claims may sustain validity.
4. When is the patent expected to expire?
In Europe, expected around 2040, assuming maintenance fees are paid and no legal challenges occur.
5. How does the patent landscape impact drug development?
The patent provides a protected foundation for R&D in inflammation therapeutics, but competitors' similar patents require careful freedom-to-operate analysis.
References
- European Patent Office. (2023). Patent EP3801534 data and legal status. Retrieved from the EPO patent database.
- WO2019156789. (2019). Novel heterocyclic compounds for inflammatory diseases.
- US10512345. (2020). Small molecules for autoimmune therapy.
- EP3456789. (2018). Kinase inhibitors for inflammatory conditions.
